A Phase 1 Study of MEDI1873 (GITR Agonist) in Adult Subjects With Select Advanced Solid Tumors

Trial Profile

A Phase 1 Study of MEDI1873 (GITR Agonist) in Adult Subjects With Select Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs MEDI 1873 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors MedImmune
  • Most Recent Events

    • 27 Apr 2017 Planned number of patients changed from 47 to 51.
    • 27 Apr 2017 Planned End Date changed from 1 Aug 2020 to 25 Feb 2021.
    • 27 Apr 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top